Moderna, Merck breakthrough could usher in cancer vaccines
Two drug companies, Moderna and Merck, tested a personalized cancer vaccine combined with an existing immunotherapy drug on melanoma patients and reported successful results in a large trial. The vaccine is designed to prevent the cancer from returning. Doctors believe this approach could eventually be used against other types of cancer.
62 across the spectrum. Choose a side on the bar to jump to it.
National story. 96 articles from 64 sources. 62 are on the bar; 2 are international, entertainment or tech outlets, listed separately. Updated Aug 22, 2026.
Left
16 sourcesModerna, Merck breakthrough could usher in cancer vaccines
What Moderna’s vaccine trial results might mean for the future of cancer care
Moderna shares surge after it says experimental mRNA cancer treatment passed key test
Center
36 sourcesRight
10 sourcesCancer vaccine prevents deadly melanoma from returning or spreading in landmark trial
Other outlets
International, entertainment and tech outlets, by their rating. Not counted in the bar above. How we count coverage
Left
2 articlesCenter
0 articlesNone
Right
0 articlesNone
The story so far
3 developments- Aug 19Moderna, Merck mRNA cancer vaccine prevents melanoma from returning in trial
- Aug 20Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments?
- Aug 21Cancer vaccine breakthrough 'a monumental leap forward'
Who covered each development
No new developments
Quiet for 58 daysLast development · Aug 21 — Cancer vaccine breakthrough 'a monumental leap forward'
The bigger story
This story is one of several related ones. Here's where it sits.